[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES8404372A1 - Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento - Google Patents

Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento

Info

Publication number
ES8404372A1
ES8404372A1 ES524511A ES524511A ES8404372A1 ES 8404372 A1 ES8404372 A1 ES 8404372A1 ES 524511 A ES524511 A ES 524511A ES 524511 A ES524511 A ES 524511A ES 8404372 A1 ES8404372 A1 ES 8404372A1
Authority
ES
Spain
Prior art keywords
inactivator
preparation
appropriate
combination
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES524511A
Other languages
English (en)
Other versions
ES524511A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of ES8404372A1 publication Critical patent/ES8404372A1/es
Publication of ES524511A0 publication Critical patent/ES524511A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/005—Stabilisers against oxidation, heat, light, ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR UN INACTIVADOR, EVENTUALMENTE EXENTO DE VIRUS DE HEPATITIS Y EVENTUALMENTE LIOFILIZABLE, DE LA CL-ESTERASA DEL SISTEMA DE COMPLEMENTO.COMPRENDE LAS SIGUIENTES OPERACIONES: PRIMERA, SE PARTE DE PLASMA HUMANO QUE CONTIENE CITRATO Y ESTA LIBRE DE CRIOGLOBULINAS Y DE FACTORES DE PROTROMBINA; SEGUNDA, SE TRATA DICHO PLASMA CON UN INTERCAMBIADOR DE ANIONES Y EL ELUATO RESULTANTE QUE CONTIENE EL INACTIVADOR CL ES FRACCIONADO CON SALES NEUTRAS; TERCERA, LAS PROTEINAS ACOMPAÑANTES DEL INACTIVADOR CL SON ABSORBIDAS CON UN ABSORBENTE HIDROFOBO; CUARTA,EL INACTIVADOR CL SE DISUELVE EN AGUA DESTILADA Y SE LE AÑADE UN AZUCAR, POR EJEMPLO SACAROSA HASTA UN 60 Y A CONTINUACION SE CALIENTA LA DISOLUCION FORMADA HASTA ALCANZAR LA TEMPERATURA DE 60 GRADOS Y SE MANTIENE A ESTA TEMPERATURA DURANTE 10 HORAS APROXIMADAMENTE; Y POR ULTIMO, SE ELIMINA LA SACAROSA DE LA DISOLUCION, MEDIANTE PRECIPITACION CON SULFATO AMONICO.
ES524511A 1982-07-30 1983-07-28 Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento Granted ES524511A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823228502 DE3228502A1 (de) 1982-07-30 1982-07-30 Verfahren zur herstellung des c1-inaktivators und seine verwendung

Publications (2)

Publication Number Publication Date
ES8404372A1 true ES8404372A1 (es) 1984-04-16
ES524511A0 ES524511A0 (es) 1984-04-16

Family

ID=6169724

Family Applications (2)

Application Number Title Priority Date Filing Date
ES524511A Granted ES524511A0 (es) 1982-07-30 1983-07-28 Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento
ES525361A Expired ES8501413A1 (es) 1982-07-30 1983-09-05 Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES525361A Expired ES8501413A1 (es) 1982-07-30 1983-09-05 Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl.

Country Status (9)

Country Link
US (1) US4915945A (es)
EP (1) EP0101935B1 (es)
JP (2) JPS5944320A (es)
AT (1) ATE19590T1 (es)
AU (1) AU564614B2 (es)
CA (1) CA1223201A (es)
DE (2) DE3228502A1 (es)
ES (2) ES524511A0 (es)
ZA (1) ZA835561B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376367B (de) * 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
FR2618784B1 (fr) * 1987-07-30 1990-04-06 Lille Transfusion Sanguine Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique
JP2729484B2 (ja) * 1988-04-28 1998-03-18 株式会社ミドリ十字 アンチトロンビン−▲ｉｉｉ▼の精製方法
US5264549A (en) * 1989-09-12 1993-11-23 The Beth Israel Hospital Association Characterization and method of isolation of factor J, an inhibitor of complement C1
US5109114A (en) * 1989-09-12 1992-04-28 Beth Israel Hospital Characterization and method of isolation for an inhibitor of complement C1
US5268363A (en) * 1989-09-12 1993-12-07 The Beth Israel Hospital Association Method of treatment to inhibit the undesirable activation of the complement cascade with factor J, an inhibitor of complement C1
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) * 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
EP0716611B1 (en) * 1993-09-01 2002-02-06 Stichting Sanquin Bloedvoorziening C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001019392A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
ES2714999T3 (es) 2011-09-24 2019-05-31 Csl Behring Gmbh Terapia de combinación que usa inmunoglobulina e inhibidor de C1
KR102022231B1 (ko) 2011-12-22 2019-09-19 체에스엘 베링 게엠베하 중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도
EP2964255B1 (en) 2013-03-08 2020-11-04 CSL Behring GmbH Treatment and prevention of remote ischemia-reperfusion injury
PL3013366T3 (pl) 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
EP3302529A4 (en) 2015-06-03 2019-02-06 The Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATING GALLENA GANGATRESIA IN NEWBORNS
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
WO2018037046A1 (en) 2016-08-23 2018-03-01 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
CA3061279A1 (en) 2017-05-16 2018-11-22 Octapharma Ag C1-esterase inhibitor preparation
JP7410019B2 (ja) 2017-09-15 2024-01-09 シーダーズ－サイナイ メディカル センター 臓器移植患者における臓器機能を改善するための方法
EP3867262A1 (en) 2018-10-17 2021-08-25 CSL Behring GmbH Process for purifying c1-inh
AU2020299425A1 (en) 2019-07-04 2022-03-03 Csl Behring Gmbh Process for purifying C1-INH
RU2769201C2 (ru) * 2020-06-23 2022-03-29 Акционерное общество "ГЕНЕРИУМ" Способ получения высокоочищенного рекомбинантного ингибитора с1-эстеразы человека для медицинского применения
AU2021381360A1 (en) 2020-11-20 2023-06-22 Csl Behring Gmbh Method for treating antibody-mediated rejection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5322139B2 (es) * 1973-11-15 1978-07-06
NL7602846A (nl) * 1976-03-18 1977-09-20 Leuven Res & Dev Vzw Antiplasmine en een antiserum daartegen.
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
JPS56154419A (en) * 1980-04-30 1981-11-30 Green Cross Corp:The Heat treatment of alpha-fetoprotein-containing aqueous solution

Also Published As

Publication number Publication date
JPS5944320A (ja) 1984-03-12
DE3228502A1 (de) 1984-02-02
ZA835561B (en) 1984-03-28
JPH07103044B2 (ja) 1995-11-08
DE3363395D1 (en) 1986-06-12
ES524511A0 (es) 1984-04-16
JPH0480886B2 (es) 1992-12-21
ES525361A0 (es) 1984-11-16
ATE19590T1 (de) 1986-05-15
EP0101935B1 (de) 1986-05-07
AU564614B2 (en) 1987-08-20
US4915945A (en) 1990-04-10
JPH05306236A (ja) 1993-11-19
CA1223201A (en) 1987-06-23
AU1745183A (en) 1984-02-02
EP0101935A1 (de) 1984-03-07
ES8501413A1 (es) 1984-11-16

Similar Documents

Publication Publication Date Title
ES8501413A1 (es) Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl.
AU542961B2 (en) Process for liquiefied natural gas
AU591788B2 (en) Combined membrane and sorption process for selective ion removal
DE3376329D1 (en) Polyterephthalates having high clarity and process for making same
AU552638B2 (en) Process for modification of coal
AU2213083A (en) Process for preparing water-dispersible granules
AU566011B2 (en) Leather treatment composition
AU517236B2 (en) Removal billion level hardness impurities
EP0083489A3 (en) Improved membrane system and process therefor
GB8301207D0 (en) Process for purifying silicon
DE3372381D1 (en) Process for purifying enzyme
GB8305007D0 (en) Wheel trim retention system
AU565364B2 (en) Carbon fibers treated with oz containing atmosphere
AU532882B2 (en) High solids mixture aeration method
DE3372974D1 (en) Reaction components containing amino groups, process for their preparation and their use
AU545486B2 (en) Process control system
AU1775483A (en) Enzymatic reaction process
PT76904A (en) Process for sweetner solution purification
AU556470B2 (en) Gas separation process
AU564056B2 (en) Gas treating process
AU555116B2 (en) Treating carbon blocks
IL69113A0 (en) Process for the preparation of shaped bodies based on polypiperazinamides
AU1024183A (en) Reducing the calcium concentration of solutions
AU564590B2 (en) Process for hybridization of cotton
AU1262188A (en) Adsorbent and process for preparing the same

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20040916